VHL and neoplasm: Prolactin II (SCG2) is markedly under-expressed in malignant tumor tissues and is correlated with shorter disease-free survival and overall survival in cancer patients.67, 68, 69 In another animal study, SCG2 suppressed the expression of VEGF via interacting with VHL tumor inhibitors in cancer cells, fostering the degradation of HIF-1α; in contrast, the accumulation of HIF-1α could effectively elevate the SCG2-mediated expression of VEGF in cancer cells.67